228 related articles for article (PubMed ID: 36642715)
1. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.
Gerber E; Asare-Werehene M; Reunov A; Burger D; Le T; Carmona E; Mes-Masson AM; Tsang BK
J Ovarian Res; 2023 Jan; 16(1):14. PubMed ID: 36642715
[TBL] [Abstract][Full Text] [Related]
2. The Application of an Extracellular Vesicle-Based Biosensor in Early Diagnosis and Prediction of Chemoresponsiveness in Ovarian Cancer.
Asare-Werehene M; Hunter RA; Gerber E; Reunov A; Brine I; Chang CY; Chang CC; Shieh DB; Burger D; Anis H; Tsang BK
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174032
[TBL] [Abstract][Full Text] [Related]
3. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance.
Manzoor HB; Asare-Werehene M; Pereira SD; Satyamoorthy K; Tsang BK
J Ovarian Res; 2024 Jan; 17(1):15. PubMed ID: 38216951
[TBL] [Abstract][Full Text] [Related]
4. Plasma Gelsolin Inhibits CD8
Asare-Werehene M; Communal L; Carmona E; Han Y; Song YS; Burger D; Mes-Masson AM; Tsang BK
Cancer Res; 2020 Sep; 80(18):3959-3971. PubMed ID: 32641415
[TBL] [Abstract][Full Text] [Related]
5. Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes.
Asare-Werehene M; Tsuyoshi H; Zhang H; Salehi R; Chang CY; Carmona E; Librach CL; Mes-Masson AM; Chang CC; Burger D; Yoshida Y; Tsang BK
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205790
[TBL] [Abstract][Full Text] [Related]
6. Exploration of Potential Diagnostic Value of Protein Content in Serum Small Extracellular Vesicles for Early-Stage Epithelial Ovarian Carcinoma.
Li P; Bai Y; Shan B; Zhang W; Liu Z; Zhu Y; Xu X; Chen Q; Sheng X; Deng X; Guo Z; Zhang D; Wang H; Zhang Y; Hu Y
Front Oncol; 2021; 11():707658. PubMed ID: 34604046
[TBL] [Abstract][Full Text] [Related]
7. Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer.
Asare-Werehene M; Communal L; Carmona E; Le T; Provencher D; Mes-Masson AM; Tsang BK
Sci Rep; 2019 Sep; 9(1):13924. PubMed ID: 31558772
[TBL] [Abstract][Full Text] [Related]
8. Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance.
Onuma T; Asare-Werehene M; Yoshida Y; Tsang BK
Cells; 2022 Oct; 11(20):. PubMed ID: 36291171
[TBL] [Abstract][Full Text] [Related]
9. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.
Asare-Werehene M; Nakka K; Reunov A; Chiu CT; Lee WT; Abedini MR; Wang PW; Shieh DB; Dilworth FJ; Carmona E; Le T; Mes-Masson AM; Burger D; Tsang BK
Oncogene; 2020 Feb; 39(7):1600-1616. PubMed ID: 31700155
[TBL] [Abstract][Full Text] [Related]
10. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
11. Plasma gelsolin levels are associated with diabetes, sex, race, and poverty.
Noren Hooten N; Mode NA; Kowalik E; Omoniyi V; Zonderman AB; Ezike N; DiNubile MJ; Levinson SL; Evans MK
J Transl Med; 2023 Mar; 21(1):190. PubMed ID: 36899335
[TBL] [Abstract][Full Text] [Related]
12. Improving SERS biosensors for the analysis of ovarian cancer-derived small extracellular vesicles.
Ngo L; Zhang W; Hnit SST; Wang Y
Analyst; 2023 Jun; 148(13):3074-3086. PubMed ID: 37306655
[TBL] [Abstract][Full Text] [Related]
13. Circulating Plasma Gelsolin: A Predictor of Favorable Clinical Outcomes in Head and Neck Cancer and Sensitive Biomarker for Early Disease Diagnosis Combined with Soluble Fas Ligand.
Chiu CT; Wang PW; Asare-Werehene M; Tsang BK; Shieh DB
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545773
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
15. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract][Full Text] [Related]
16. Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers.
Huang H; Li Y; Liu J; Zheng M; Feng Y; Hu K; Huang Y; Huang Q
PLoS One; 2012; 7(12):e51256. PubMed ID: 23251472
[TBL] [Abstract][Full Text] [Related]
17. Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy.
Nadkarni NA; Rajakumar A; Mokhashi N; Burke SD; Rana S; Salahuddin S; Dang Q; Thadhani R; Krishnan R; Stossel TP; Karumanchi SA
Pregnancy Hypertens; 2016 Oct; 6(4):333-339. PubMed ID: 27939478
[TBL] [Abstract][Full Text] [Related]
18. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
[TBL] [Abstract][Full Text] [Related]
19. Identifying Serum Small Extracellular Vesicle MicroRNA as a Noninvasive Diagnostic and Prognostic Biomarker for Ovarian Cancer.
Li L; Zhang F; Zhang J; Shi X; Wu H; Chao X; Ma S; Lang J; Wu M; Zhang D; Liang Z
ACS Nano; 2023 Oct; 17(19):19197-19210. PubMed ID: 37750402
[TBL] [Abstract][Full Text] [Related]
20. Low Plasma Gelsolin Concentrations in Chronic Granulomatous Disease.
Audley J; Gliniewicz EF; Zarember KA; Hong HS; Wald G; Kuhns DB; Kang E; Malech HL; Suffredini AF; Noveck RJ; Dinubile MJ; Levinson SL; Stossel TP; Gallin JI
Inflammation; 2021 Feb; 44(1):270-277. PubMed ID: 32886268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
